Taiwan Liposome Co. Ltd., of Taipei, Taiwan, said its recruited 40 patients for its phase I/II trial of TLC599, with data readout expected in the second half of this year following the 12-week observation period. The study is testing TLC599, a new formulation entrapping a corticosteroid using TLC's sustained-release platform, Bioseizer, and administered as a local injection for treating osteoarthritis.